Targets › IMPDH1
4 programs from 4 companies in 23 trials: 8 Phase 4, 8 Phase 2, 5 Phase 1, 2 Phase 3; Genitourinary, Infectious disease, Oncology; next expected readout Nov 2026.
Catalyzes the conversion of inosine 5'-phosphate (IMP) to xanthosine 5'-phosphate (XMP), the first committed and rate-limiting step in the de novo synthesis of guanine nucleotides, and therefore plays an important role in the regulation of cell growth. Could also have a single-stranded nucleic acid-binding activity and could play a role in RNA and/or DNA metabolism. (UniProt, P20839)
Open in Phaseline: the race on IMPDH1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Chong Kun Dang Pharmaceutical | Mycophenolate Mofetil Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor | IMPDH1, IMPDH2 | Phase 4 | Kidney Transplantation; Hypersensitivity Pneumonitis; Liver Transplantation; Lupus Nephritis … | Nov 2026 |
| Mats Heyman | Thioguanine Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor | IMPDH1, IMPDH2 | Phase 3 | Leukemia, Acute Lymphoblastic | Jun 2033 |
| Roche | Mycophenolate Mofetil Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor | IMPDH1, IMPDH2 | Phase 3 | Childhood Idiopathic Nephrotic Syndrome | – |
| University of Oxford | Ribavirin Inosine-5'-monophosphate dehydrogenase 1 inhibitor; RNA-directed RNA polymerase inhibitor | IMPDH1 | Phase 2 | Respiratory Syncytial Virus | Jan 2027 |
Kidney Transplantation (4) Lupus Nephritis (2) Hypersensitivity Pneumonitis (1) Liver Transplantation (1) IgA Nephropathy (1) Systemic Sclerosis With Lung Involvement (1) Acute Myelogenous Leukemia (1) Immune-mediated Hepatitis (1) Lymphoma, Non-Hodgkin (1) Hematological Malignancies (1) Immunodeficiency (1) Graft Versus Host Disease (1)
small molecule (2), mixed (2)
Chong Kun Dang Pharmaceutical (1) Mats Heyman (1) University of Oxford (1) Roche (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.